FULC Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 69.26% compared to Fulcrum Therapeutics's net margin of -49.65%. Fulcrum Therapeutics's return on equity of -8.07% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Fulcrum Therapeutics has a consensus price target of $5.29, signalling upside risk potential of 4.05%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 503.14%. Given that NovaBay Pharmaceuticals has higher upside potential than Fulcrum Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Fulcrum Therapeutics.

Fulcrum Therapeutics has a beta of 2.056, which suggesting that the stock is 105.635% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Fulcrum Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulcrum Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Fulcrum Therapeutics quarterly revenues are $80M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Fulcrum Therapeutics's net income of -$21.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Fulcrum Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 69.26% compared to Fulcrum Therapeutics's net margin of -2357.27%. Fulcrum Therapeutics's return on equity of -8.07% beat Palatin Technologies's return on equity of --.

Fulcrum Therapeutics has a consensus price target of $5.29, signalling upside risk potential of 4.05%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1140.88%. Given that Palatin Technologies has higher upside potential than Fulcrum Therapeutics, analysts believe Palatin Technologies is more attractive than Fulcrum Therapeutics.

Fulcrum Therapeutics has a beta of 2.056, which suggesting that the stock is 105.635% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Fulcrum Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulcrum Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Fulcrum Therapeutics quarterly revenues are $80M, which are larger than Palatin Technologies quarterly revenues of $350K. Fulcrum Therapeutics's net income of -$21.7M is lower than Palatin Technologies's net income of -$7.8M. Notably, Fulcrum Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 69.26% compared to Fulcrum Therapeutics's net margin of 7.2%. Fulcrum Therapeutics's return on equity of -8.07% beat Sarepta Therapeutics's return on equity of 12.48%.

Fulcrum Therapeutics has a consensus price target of $5.29, signalling upside risk potential of 4.05%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.96 which suggests that it could grow by 47.25%. Given that Sarepta Therapeutics has higher upside potential than Fulcrum Therapeutics, analysts believe Sarepta Therapeutics is more attractive than Fulcrum Therapeutics.

Fulcrum Therapeutics has a beta of 2.056, which suggesting that the stock is 105.635% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.770, suggesting its less volatile than the S&P 500 by 22.964%.

Fulcrum Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulcrum Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Fulcrum Therapeutics quarterly revenues are $80M, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Fulcrum Therapeutics's net income of -$21.7M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Fulcrum Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 82.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics is -- versus 7.75x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 69.26% compared to Fulcrum Therapeutics's net margin of --. Fulcrum Therapeutics's return on equity of -8.07% beat Theriva Biologics's return on equity of --.

Fulcrum Therapeutics has a consensus price target of $5.29, signalling upside risk potential of 4.05%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 5591.82%. Given that Theriva Biologics has higher upside potential than Fulcrum Therapeutics, analysts believe Theriva Biologics is more attractive than Fulcrum Therapeutics.

Fulcrum Therapeutics has a beta of 2.056, which suggesting that the stock is 105.635% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.

Fulcrum Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulcrum Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Fulcrum Therapeutics quarterly revenues are $80M, which are larger than Theriva Biologics quarterly revenues of --. Fulcrum Therapeutics's net income of -$21.7M is lower than Theriva Biologics's net income of -$7.7M. Notably, Fulcrum Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics is -- versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.